| Active Not Recruiting | Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers NCT07162181 | Eli Lilly and Company | Phase 2 |
| Enrolling By Invitation | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring NCT06788509 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias NCT06364423 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocyt NCT05963074 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With C NCT06299540 | Janssen Cilag S.A.S. | — |
| Withdrawn | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adu NCT06205290 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 3 |
| Recruiting | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refract NCT05947851 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obin NCT05650723 | Weill Medical College of Cornell University | Phase 2 |
| Active Not Recruiting | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or NCT05515406 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory NCT05244070 | Bristol-Myers Squibb | Phase 1 |
| Active Not Recruiting | A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With No NCT05424822 | Janssen Research & Development, LLC | Phase 1 |
| Withdrawn | Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL NCT05259813 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers NCT05024045 | Eli Lilly and Company | Phase 1 |
| Completed | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL NCT04876092 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) NCT04849416 | Eli Lilly and Company | Phase 2 |
| Completed | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) NCT04540796 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia NCT04210219 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma NCT04271800 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (C NCT04204057 | Rhizen Pharmaceuticals SA | Phase 2 |
| Completed | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cel NCT03190330 | Johnson & Johnson Private Limited | Phase 4 |
| Unknown | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma NCT04271410 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Completed | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CL NCT03900598 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World S NCT03720561 | Janssen-Cilag S.p.A. | — |
| Terminated | DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic NCT03265717 | Invectys | Phase 2 |
| Completed | Project to Improve Communication About Serious Illness - Pilot Study NCT03746392 | University of Washington | N/A |
| Unknown | CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT NCT03685786 | Shenzhen Second People's Hospital | Phase 1 |
| Completed | Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated Wi NCT03476655 | Johnson & Johnson Private Limited | — |
| Active Not Recruiting | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-li NCT03462719 | Janssen Research & Development, LLC | Phase 3 |
| Withdrawn | This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI NCT03343678 | Boehringer Ingelheim | Phase 1 |
| Recruiting | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Le NCT03331198 | Juno Therapeutics, a Subsidiary of Celgene | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 NCT03301207 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Determination of Blood Tumor Cells NCT04290923 | University of Zurich | — |
| Completed | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Sma NCT03204188 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) NCT03289182 | Hoffmann-La Roche | — |
| Unknown | Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients NCT02912754 | Sunnybrook Health Sciences Centre | Phase 1 / Phase 2 |
| Unknown | Treatment of Chronic Lymphocytic Leukemia NCT02757586 | Peking University People's Hospital | — |
| Unknown | Combination of Ibrutinib and As2O3 in the Treatment of CLL NCT02757040 | Peking University People's Hospital | Phase 3 |
| Completed | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL NCT02639910 | MorphoSys AG | Phase 2 |
| Completed | A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance NCT02842229 | Celgene | — |
| Withdrawn | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ib NCT02743546 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignanci NCT02846584 | Southwest Hospital, China | Phase 2 |
| Completed | Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-trea NCT02759016 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clin NCT03425591 | Janssen-Cilag Ltd. | — |
| Completed | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Sub NCT02733042 | Celgene | Phase 1 / Phase 2 |
| Unknown | Humanized CAR-T Therapy for Treatment of B Cell Malignancy NCT02782351 | Kai Lin Xu; Jun Nian Zheng | Phase 1 / Phase 2 |
| Completed | Phase II Trial GA101 Inbrutinib B CLL NCT02666898 | French Innovative Leukemia Organisation | Phase 2 |
| Completed | A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab NCT02406742 | Celgene | Phase 1 / Phase 2 |
| Terminated | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies NCT02454270 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Terminated | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL NCT02361346 | Molecular Templates, Inc. | Phase 1 / Phase 2 |
| Completed | Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymph NCT01732861 | Celgene | Phase 1 |
| Completed | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT01744626 | Celgene Corporation | Phase 1 |
| Completed | Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) NCT01373229 | David Rizzieri, MD | Phase 1 |
| Withdrawn | Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia NCT01456182 | Afexa Life Sciences Inc | Phase 1 |
| Completed | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors NCT01158118 | Washington University School of Medicine | Phase 2 |
| Completed | BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) NCT01296932 | Boehringer Ingelheim | Phase 1 |
| Terminated | A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory NCT01005979 | Emory University | Phase 1 |
| Completed | A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocyti NCT00923182 | Genzyme, a Sanofi Company | Phase 1 |
| Completed | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle C NCT00861510 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Terminated | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) NCT00871546 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) NCT00951457 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 1 / Phase 2 |
| Completed | Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL NCT00738829 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 1 / Phase 2 |
| Terminated | A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphoc NCT00768339 | Aegera Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia NCT00545714 | Hoffmann-La Roche | Phase 2 |
| Completed | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) NCT00871663 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Institut Paoli Calmettes Chronic Lymphatic Leukemia Database NCT02869529 | Institut Paoli-Calmettes | — |
| Completed | Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) NCT00206726 | Genzyme, a Sanofi Company | Phase 2 |
| Recruiting | Family Study of Lymphoproliferative Disorders NCT00626496 | Mayo Clinic | — |
| Completed | A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocy NCT00220311 | Genzyme, a Sanofi Company | Phase 4 |
| Approved For Marketing | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer NCT05172700 | Loxo Oncology, Inc. | — |